News

Early administration of such therapies in this patient group not shown to help mortality rates.

A brief update on today's infectious disease news.

A review of 61 clinical trials suggests that acute uncomplicated cystitis in adult women could be treated with shorter duration of antibiotics in some cases.

The test uses whole blood, plasma, or serum. The testing kit is intended to produce reliable results within 10 minutes.

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

An assessment of 21 pediatric cases leads France investigators to believe development is due to post-viral immunological reactions.

Mild symptoms may still present high risk for SARS-CoV-2 transmission.

A quick brief on today's top infectious disease news.

Due to health concerns, the US FDA is reissuing some EUAs to clarify which respirators are suited for decontamination and reuse.

SARS-CoV-2 arrived in Northern California through a complicated series of introductions internationally and between states.

Mary Schmidt, MD, discusses challenges in translating infectious disease advice to policy action.

An in-depth look at the factors associated with the progression to CDI in colonized patients reveals specific risks that may guide future management of this vulnerable population.

The following is a roundup of the latest ID pipeline developments.

Pinar Karaca-Mandic, PhD, explains new research showing how exponentional rates of hospitalizations were avoided in 4 shut-down states.

Jason Pogue, PharmD, BCPS, BCIDP, speaks about the state of publishing during the COVID-19 pandemic.

The following are notable recall statements released by the US Food and Drug Administration during the week of May 31-June 7.

A brief on today's top ID news.

Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.

John Strotbeck, CEO of Boathouse Sports, discusses results of physical distancing measures at the firm's COVID-adapted factory.

The only new drug approved for COVID-19 treatment has limited efficacy, but is still desperately needed to fight pandemic.

Adam Brufsky, MD, PhD, addresses the potential for changing dynamics in SARS-CoV-2.

An assessment observing 4 states under stay-at-home orders showed all avoided worsened outcomes of severe infection rates.

The Merck combination antibiotic has been previously approved for cUTIs and complicated intra-abdominal infections.

Clinicians and researchers have questioned the likelihood of assembling the quantity of data supplied by Surgisphere on hydroxychloroquine in such a short period of time.

A brief on the latest infectious disease headlines.

Matthew F. Pullen, MD, co-author of the recent hydroxychloroquine prophylaxis trial, shares the top clinical takeaways.

The test measures IL-6 to identify patients with COVID-19 at high risk of intubation.

About two-thirds of patients that reported loss of smell associated with viral infection actually had confirmed anosmia after objective olfactory testing.

Antimicrobial stewardship education was conducted with de-identified provider-specific prescribing scorecards.

Though most trace the coronavirus outbreak to China, a new analysis finds most of the cases in New York seem to have originated in Europe.